Abrupt Discontinuation of Fenfluramine and Dexfenfluramine May Cause Serotonin Withdrawal Syndrome

Abstract

Get full access to this article

View all access options for this article.

References

FDA News release, September 15, 1997.

Rubin

. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995; 75 (suppl): 51–4A.

Bever

Perry

. Dexfenfluramine hydrochloride: An anorexigenic agent. Am J Health-Syst Pharm 1997; 54: 2059–72.

D'Arcy

. Warnings from the UK Committee on Safety of Medicines: Pulmonary hypertension with fenfluramine and dexfenfluramine. Int J Pharm 1992; 6: 217–8.

Connolly

Crary

McGoon

Hensrud

Edwards

, Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med 1997; 337: 581–8.

Robiolio

Rigolin

Wilson

, Carcinoid heart disease: Correlation of high serotonin level with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92: 790–5.

Redfield

Nicholson

Edwards

, Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations. Ann Intern Med 1992; 117: 50–2.

Package insert. Redux (dexfenfluramine). Lexington, MA: Wyeth-Ayerst Company, April 1996.

Abenhaim

Moride

Brenot

, Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609–16.

10.

Lazowick

Jamison

. Dexfenfluramine for the treatment of obesity. Pharm Ther J 1996; 21: 417–21.

11.

Lazowick

Levin

. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 1995; 29: 1284–5.

12.

Discontinuation Consensus Panel. Antidepressant discontinuation syndrome: Update on serotonin reuptake inhibitors. J Clin Psychiatry 1997; 58 (suppl 7): 3–40.

13.

Oswald

Lewis

Dunleavy

DLF

, Drugs of dependence though not of abuse: Fenfluramine and imipramine. Br Med J 1971; 3: 70–3.

14.

Lejoyeux

Ades

Maurad

Solomon

Dilsaver

. Antidepressant withdrawal syndrome: Recognition, prevention and management. CNS Drugs 1996; 5: 278–92.

15.

Otani

Tanaka

Kaneko

, Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994; 9: 131–3.

16.

Zajecka

Tracy

Mitchell

. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 1997; 58: 291–7.

17.

Coupland

Bell

Potokar

. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16: 356–62.

18.

Pinder

Brogden

Sawyer

, Fenfluramine: A review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975; 10: 241–323.

19.

Steel

Briggs

. Withdrawal depression in obese patients after fenfluramine treatment. Br Med J 1972; 3: 26–7.

20.

Bowen

Spring

Fox

. Tryptophan and high-carbohydrate diets as adjuncts to smoking cessation therapy. J Behav Med 1991; 14: 91–110.

21.

Akaoka

Aston-Jones

. Indirect serotonergic agonist attenuate neuronal opiate withdrawal. Neuroscience 1993; 54: 561–5.

22.

Spring

Wurtman

Gleason

, Weight gain and withdrawal symptoms after smoking cessation: A preventive intervention using d-fenfluramine. Health Psychol 1991; 10: 216–23.

23.

Nutt

Cowen

. Diazepam alters brain 5-HT function in man: Implications for the acute and chronic effects of benzodiazepines. Psychol Med 1987; 17: 601–7.

24.

Tabakoff

Hoffman

Moses

. Neurochemical correlates of ethanol withdrawal: Alterations in serotonergic function. J Pharm Pharmacol 1977; 29: 471–6.

25.

Dilsaver

Greden

. Antidepressant withdrawal phenomena. Biol Psychiatry 1984; 19: 237–56.